A Randomized, Double-blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of FP-025, an MMP-12 Inhibitor, in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs FP 025 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Foresee Pharmaceuticals
- 22 Sep 2017 Planned number of patients changed from 100 to 80.
- 22 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 22 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.